The Latest Breaking News from BIIB

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure.

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more.

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.